Additional brain scan could provide more certainty in diagnosing foetal brain abnormalities
An additional MRI scan during pregnancy could help to more accurately detect foetal abnormalities and give more certainty for parents whose 20-week ultrasound scan showed a potential problem, according to new research by scientists at the University of Sheffield.
The study involved 570 women whose mid-pregnancy ultrasound scan revealed a potential brain abnormality in the foetus. Within two weeks of their first scan they were given an extra scan using MRI, which increased accuracy of the diagnosis, meaning almost all (93 per cent) were correct.
This extra information helped doctors give a more accurate diagnosis and advice to parents.
In comparison, the mid-pregnancy scan alone was correct in two-thirds of cases (68 per cent). The accuracy of the scans was confirmed by scanning babies after birth or by autopsy for miscarriages and terminations.
The mid-pregnancy scan is an ultrasound scan given between 18 and 21 weeks of pregnancy to detect major physical abnormalities such as spina bifida, cleft lip, and heart and brain abnormalities. If a problem is found, women are referred for more tests and in some cases are offered a termination or counselling.
Brain abnormalities occur in three in every 1000 pregnancies and in some cases cause miscarriage or stillbirth.
Lead author, Professor Paul Griffiths from the University of Sheffield’s Department of Infection, Immunity & Cardiovascular Disease, said: “This study is the first of its kind and has shown that adding an MRI scan when a problem is detected provides additional information to support parents making decisions about their pregnancy.
“Based on our findings we propose that an MRI scan should be given in any pregnancy where the foetus may have a suspected brain abnormality.”
In the study, doctors analysing the MRI and ultrasound scans were asked to rate how confident they were of their diagnosis. The study also analysed how the MRI result changed the prognosis and advice given by doctors.
The MRI gave extra information about the brain abnormality in half of cases (49 per cent, 387 of 783).
For example, in one case the MRI confirmed the ultrasound diagnosis and identified an additional abnormality. This information allowed doctors to give parents a more certain outlook, halving (55 per cent) the number of cases in the ‘unknown’ prognosis group and increasing the number of pregnancies predicted to be ‘normal’ (135 per cent), ‘favourable’ (18 per cent) or ‘poor’ (56 per cent).
Doctors agreed that the extra MRI scan changed the outlook for the pregnancy in at least a fifth of cases (20 per cent, 157 of 783). And as a result this changed how the pregnancy was managed in one in three cases (34 per cent, 269 of 783), with terminations offered in an extra 11 per cent of cases (84 of 783) after the MRI and parents seeking counselling in 15 per cent more cases (115 of 783).
Doctors using MRI were more confident of their diagnosis – saying they had ‘high confidence’ in 95 per cent of cases (544 of 570), compared with 82 per cent (465 of 570 cases) for doctors using ultrasound. In addition, 95 per cent (257 of 270) of mothers said that they would have an MRI scan if a future pregnancy showed a brain abnormality and around 80 per cent (227 of 277) said that the information from the scan helped them better understand their baby’s condition.
There will now be further analysis of the trial’s results, including a health economics analysis, to confirm if the extra scan should be used routinely. Within the study, two foetuses (of 570, less than one per cent) were diagnosed correctly by the ultrasound and incorrectly by the MRI.
Only cases identified by the ultrasound scan were given the extra MRI, so any cases where an ultrasound did not identify an abnormality would not have been included in this study.
Professor Rod Scott of the University of Vermont in the USA, commented on the importance of the research: “Accurate diagnosis of significant brain abnormalities has important therapeutic implications. Consequently, it is essential that tools used for prenatal diagnosis are rigorously evaluated… This trial strongly supports the view that in utero Magnetic Resonance (iuMR) imaging is an excellent technique, and it should be incorporated into clinical practice as soon as possible.”
The study was funded by the National Institute for Health Research Health Technology Assessment programme. It was conducted by scientists from University of Sheffield, Newcastle University, University of Birmingham, Birmingham Women’s Foundation Trust and Leeds Teaching Hospitals NHS Trust.
The University of Sheffield
With almost 27,000 of the brightest students from over 140 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world’s leading universities.
A member of the UK’s prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.
Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.
Sheffield is the only university to feature in The Sunday Times 100 Best Not-For-Profit Organisations to Work For 2016 and was voted number one university in the UK for Student Satisfaction by Times Higher Education in 2014. In the last decade it has won four Queen’s Anniversary Prizes in recognition of the outstanding contribution to the United Kingdom’s intellectual, economic, cultural and social life.
Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.
Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.
Media Relations Officer
University of Sheffield
0114 222 9859